Evidence map›Paper›PMID 35327524›Full record

ArticleBiomedicines2022

Anticancer Effects with Molecular Docking Confirmation of Newly Synthesized Isatin Sulfonamide Molecular Hybrid Derivatives against Hepatic Cancer Cell Lines.

Mahmoud Eldeeb, Eman F Sanad, Ahmed Ragab, Yousry A Ammar, Khaled Mahmoud, Mamdouh M Ali, Nadia M Hamdy

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Design, synthesis and molecular modeling of isatin-aminobenzoic acid hybrids as antibacterial and antibiofilm agents.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mahmoud EldeebDepartment of Biochemistry, Biotechnology Research Institute, National Research Centre, 12622 Giza, Egypt.
Eman F SanadBiochemistry and Molecular Biology Department, Faculty of Pharmacy, Ain Shams University, 11566 Cairo, Egypt.ORCID 0000-0001-5406-2029
Ahmed RagabDepartment of Chemistry, Faculty of Science (for Boys, Cairo Branch), Al-Azhar University, 11884 Cairo, Egypt.ORCID 0000-0001-8542-7465
Yousry A AmmarDepartment of Chemistry, Faculty of Science (for Boys, Cairo Branch), Al-Azhar University, 11884 Cairo, Egypt.
Khaled MahmoudDepartment of Pharmacognosy, Pharmaceutical and Drug Industries Research Institute, National Research Centre, 12622 Giza, Egypt.
Mamdouh M AliDepartment of Biochemistry, Biotechnology Research Institute, National Research Centre, 12622 Giza, Egypt.
Nadia M HamdyBiochemistry and Molecular Biology Department, Faculty of Pharmacy, Ain Shams University, 11566 Cairo, Egypt.ORCID 0000-0003-2105-107X
National Research Centre · EGAin Shams University · EGAl-Azhar University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current study investigated the cytotoxic effect of ten sulfonamide-derived isatins, following molecular hybridization, based on the association principles, on hepatocellular carcinoma (HCC) HepG2 and Huh7 cell lines, compared for safety using human normal retina pigmented epithelial (RPE-1) cells. The ten compounds showed variable in vitro cytotoxicity on HepG2 and Huh7 cells, using the MTT assay. Four compounds (4/10) were highly cytotoxic to both HepG2 and HuH7. However, only 3 of these 4 were of the highest safety margin on RPE-1 cells in vitro and in the

Indexed as

angiogenesisapoptosiscancer hallmarksEGFR tyrosine kinase inhibitorHepG2Huh7invasionisatin sulfonamidesmolecular docking

Identifiers

PMID35327524
PMCPMC8945686
OpenAlexW4220965971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.